Miniatura

Fitxers

726806.pdf (6.07 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-11-14

Llicència de publicació

cc-by (c) Devis Jauregui, Laura et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/192260

Generation and integrated analysis of advanced patient-derived orthoxenograft models (PDOX) for the rational assessment of targeted therapies in endometrial cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/advs.202204211

Resum

Clinical management of endometrial cancer (EC) is handicapped by the limited availability of second line treatments and bona fide molecular biomarkers to predict recurrence. These limitations have hampered the treatment of these patients, whose survival rates have not improved over the last four decades. The advent of coordinated studies such as The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma (TCGA_UCEC) has partially solved this issue, but the lack of proper experimental systems still represents a bottleneck that precludes translational studies from successful clinical testing in EC patients. Within this context, the first study reporting the generation of a collection of endometrioid-EC-patient-derived orthoxenograft (PDOX) mouse models is presented that is believed to overcome these experimental constraints and pave the way toward state-of-the-art precision medicine in EC. The collection of primary tumors and derived PDOXs is characterized through an integrative approach based on transcriptomics, mutational profiles, and morphological analysis; and it is demonstrated that EC tumors engrafted in the mouse uterus retain the main molecular and morphological features from analogous tumor donors. Finally, the molecular properties of these tumors are harnessed to assess the therapeutic potential of trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor with growing interest in EC, using patient-derived organotypic multicellular tumor spheroids and in vivo experiments.

Matèries

Càncer d'endometri, Tumors, Experimentació animal

Matèries (anglès)

Endometrial cancer, Tumors, Animal experimentation

Citació

Col·leccions

Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

DEVIS JAUREGUI, Laura, VIDAL-BEL, August, PLATA PEÑA, Laura, SANTACANA, Maria, GARCÍA MULERO, Sandra, BONIFACI CANO, Núria, NOGUERA-DELGADO, Eulàlia, RUIZ, Nuria, GIL, Marta, DORCA DUCH, Eduard, LLOBET, Francisco j., COLL-IGLESIAS, Laura, GASSNER, Katja, MARTÍNEZ INIESTA, María, RODRIGUEZ BARRUECO, Ruth, BARAHONA, Marc, MARTÍ, Lola, VIÑALS CANALS, Francesc, PONCE I SEBASTIÀ, Jordi, SANZ PAMPLONA, Rebeca, PIULATS, Josep m., VIVANCOS, Ana, MATIAS-GUIU, Xavier, VILLANUEVA GARATACHEA, Alberto, LLOBET NAVAS, David. Generation and integrated analysis of advanced patient-derived orthoxenograft models (PDOX) for the rational assessment of targeted therapies in endometrial cancer. _Advanced Science_. 2022. Vol. 10, núm. 1, pàgs. e2204211. [consulta: 25 de febrer de 2026]. ISSN: 2198-3844. [Disponible a: https://hdl.handle.net/2445/192260]

Exportar metadades

JSON - METS

Compartir registre